Tomihiro Imai

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Friedreich‐like ataxia with retinitis pigmentosa caused by the His¹⁰¹Gln mutation of the α‐Tocopherol transfer protein gene

Takanori Yokota, Toshiaki Shiojiri, Takanari Gotoda et al. · Annals of Neurology · 1997 · 138 citations

Genetics, Pathology, Molecular Biology +17

Health‐related quality‐of‐life and treatment targets in myasthenia gravis

Kimiaki Utsugisawa, Shigeaki Suzuki, Yuriko Nagane et al. · Muscle & Nerve · 2014 · 93 citations

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text